Congenital heart disease cardiac catheterization at Uganda Heart Institute, a 12-year retrospective study of immediate outcomes.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
29 Aug 2024
Historique:
received: 01 03 2024
accepted: 30 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

Cardiac catheterization is an invasive diagnostic and treatment tool for congenital heart disease (CHD) with potential complications. To describe the immediate outcomes of patients who underwent cardiac catheterization for CHD at the Uganda Heart Institute (UHI). The study was a retrospective chart review of 857 patients who underwent cardiac catheterization for CHD at UHI from 1st February 2012 to 30th June 2023. Precardiac catheterization clinical data, procedure details, and post-procedure data were recorded. The statistical software SPSS was used for data analysis. We studied 857 patients who underwent cardiac catheterization for CHD at UHI. Females comprised 62.8% (n = 528). The age range was 3 days to 64 years, with a mean of 5.1 years (SD 7.4). Advanced heart failure was present in 24(2.8%) of the study participants. The most common procedures were patent ductus arteriosus device closure (n = 500, 58.3%), diagnostic catheterization (n = 194, 22.5%), and balloon pulmonary valvuloplasty (n = 114, 13.0%). PDA device closure had 89.4% optimal results while BPV had 75.9% optimal performance outcome. Adverse events occurred in 52 out of 857 study participants (6.1%). Clinically meaningful adverse events (CMAES) occurred in 3.9%, (n = 33), high severity adverse events in 2.9% (n = 25) and mortality in 1.5% (n = 13). Advanced heart failure at the time of cardiac catheterization, was significantly associated with clinically meaningful adverse events (OR 52 p-value < 0.001) and mortality (OR 564, p value < 0.001). Many patients with CHD have benefited from the cardiac catheterization program at UHI with high optimal procedure outcome results. Patients with advanced heart failure at the time of cardiac catheterization have less favorable outcomes emphasizing the need for early detection and early intervention.

Sections du résumé

BACKGROUND BACKGROUND
Cardiac catheterization is an invasive diagnostic and treatment tool for congenital heart disease (CHD) with potential complications.
OBJECTIVE OBJECTIVE
To describe the immediate outcomes of patients who underwent cardiac catheterization for CHD at the Uganda Heart Institute (UHI).
METHODS METHODS
The study was a retrospective chart review of 857 patients who underwent cardiac catheterization for CHD at UHI from 1st February 2012 to 30th June 2023. Precardiac catheterization clinical data, procedure details, and post-procedure data were recorded. The statistical software SPSS was used for data analysis.
RESULTS RESULTS
We studied 857 patients who underwent cardiac catheterization for CHD at UHI. Females comprised 62.8% (n = 528). The age range was 3 days to 64 years, with a mean of 5.1 years (SD 7.4). Advanced heart failure was present in 24(2.8%) of the study participants. The most common procedures were patent ductus arteriosus device closure (n = 500, 58.3%), diagnostic catheterization (n = 194, 22.5%), and balloon pulmonary valvuloplasty (n = 114, 13.0%). PDA device closure had 89.4% optimal results while BPV had 75.9% optimal performance outcome. Adverse events occurred in 52 out of 857 study participants (6.1%). Clinically meaningful adverse events (CMAES) occurred in 3.9%, (n = 33), high severity adverse events in 2.9% (n = 25) and mortality in 1.5% (n = 13). Advanced heart failure at the time of cardiac catheterization, was significantly associated with clinically meaningful adverse events (OR 52 p-value < 0.001) and mortality (OR 564, p value < 0.001).
CONCLUSION CONCLUSIONS
Many patients with CHD have benefited from the cardiac catheterization program at UHI with high optimal procedure outcome results. Patients with advanced heart failure at the time of cardiac catheterization have less favorable outcomes emphasizing the need for early detection and early intervention.

Identifiants

pubmed: 39210275
doi: 10.1186/s12872-024-04085-6
pii: 10.1186/s12872-024-04085-6
pmc: PMC11360719
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

463

Informations de copyright

© 2024. The Author(s).

Références

Pediatr Cardiol. 2015 Apr;36(4):873-9
pubmed: 25577228
Circ Res. 2017 Mar 17;120(6):1015-1026
pubmed: 28302745
J Pediatr. 1978 Jul;93(1):97-101
pubmed: 650356
Sci Rep. 2020 Aug 19;10(1):14001
pubmed: 32814787
Circulation. 2011 Jun 7;123(22):2607-52
pubmed: 21536996
Indian Heart J. 2002 Mar-Apr;54(2):164-9
pubmed: 12086379
Korean Circ J. 2016 Mar;46(2):246-55
pubmed: 27014356
Catheter Cardiovasc Interv. 2008 Aug 1;72(2):278-85
pubmed: 18546231
Pediatr Cardiol. 2015 Oct;36(7):1363-75
pubmed: 25991570
Thorax. 2003 Sep;58(9):797-800
pubmed: 12947142
J Soc Cardiovasc Angiogr Interv. 2023 Oct 03;2(6Part A):101119
pubmed: 39129900
Circ Cardiovasc Interv. 2024 Mar;17(3):e012834
pubmed: 38258562
J Cardiol. 2010 Sep;56(2):183-8
pubmed: 20541909
Pulm Circ. 2013 Dec;3(4):831-9
pubmed: 25006398
World J Cardiol. 2020 Jun 26;12(6):269-284
pubmed: 32774779
Br Heart J. 1993 Sep;70(3):297-300
pubmed: 8398509
Glob Heart. 2021 Feb 09;16(1):11
pubmed: 33598391
JACC Adv. 2023 May 24;2(4):100344
pubmed: 38938241
Afr Health Sci. 2020 Jun;20(2):745-752
pubmed: 33163039
Am J Cardiol. 2000 Dec 1;86(11):1275-8, A9
pubmed: 11090810
Circulation. 1968 May;37(5 Suppl):III1-4
pubmed: 4953142
Catheter Cardiovasc Interv. 2010 Feb 15;75(3):389-400
pubmed: 19885913
J Am Heart Assoc. 2022 Jan 4;11(1):e022832
pubmed: 34935425
J Am Coll Cardiol. 1992 May;19(6):1285-93
pubmed: 1564229
Catheter Cardiovasc Interv. 2021 Jan 1;97(1):127-134
pubmed: 32294315
J Am Coll Cardiol. 1998 Nov;32(5):1433-40
pubmed: 9809959
Front Pediatr. 2016 Jun 13;4:59
pubmed: 27379218
Turk J Pediatr. 2000 Oct-Dec;42(4):294-7
pubmed: 11196745
J Heart Lung Transplant. 2015 Mar;34(3):376-80
pubmed: 25813766
Radiology. 2005 Apr;235(1):177-83
pubmed: 15731373
Br Heart J. 1991 Feb;65(2):109-12
pubmed: 1867944
Am J Cardiol. 1995 Mar 15;75(8):642-5
pubmed: 7887401
Catheter Cardiovasc Interv. 2013 Sep 1;82(3):454-62
pubmed: 23436592
J Am Coll Cardiol. 1997 Sep;30(3):811-6
pubmed: 9283545
Johns Hopkins Med J. 1972 Sep;131(3):247-58
pubmed: 5075527
Cardiol Young. 1999 May;9(3):266-72
pubmed: 10386695

Auteurs

Nestor Mbabazi (N)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda. mbabazinestor3@gmail.com.
Mulago National Referral Hospital, Kampala, Uganda. mbabazinestor3@gmail.com.

Twalib Aliku (T)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.
Uganda Christian University School of Medicine, Mukono, Uganda.

Judith Namuyonga (J)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.
Makerere University College of Health Sciences, Kampala, Uganda.

Hilda Tumwebaze (H)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.

Emma Ndagire (E)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.

Bernard Obongonyinge (B)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.

Rebecca Esther Khainza (RE)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.
Mulago National Referral Hospital, Kampala, Uganda.

Mary Teddy Akech (MT)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.

Killen Angelline (K)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.
John. Fitzgerald Kennedy Hospital, 22nd Street Sinkor, Monrovia, Liberia.

Aisha Nakato (A)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.
Bombo General Military Hospital, Bombo, Uganda.

Cornelius Ssendagire (C)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.
Makerere University College of Health Sciences, Kampala, Uganda.

Lameck Ssemogerere (L)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.
Makerere University College of Health Sciences, Kampala, Uganda.

Michael Oketcho (M)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.

John Omagino (J)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.

Peter Lwabi (P)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.

Sulaiman Lubega (S)

Uganda Heart Institute, P.O. Box 3792, Kampala, Uganda.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH